Pre-Surgical Tirzepatide for Weight Loss in Prostate Cancer
This study is looking at how well a weight loss program using the drug tirzepatide works for men who are overweight or obese and have intermediate-risk prostate cancer. The goal is to see if tirzepatide can help with weight loss before they have surgery (radical prostatectomy) to remove their prostate. You might be able to join if you are an adult man with localized prostate cancer that meets specific criteria, including certain tumor characteristics and PSA levels. The study aims to enroll 30 participants and will measure how many people join, stay in the study, and follow the treatment plan. The main focus is on the safety of tirzepatide.
- Study design
- This is an interventional study, meaning participants will receive a specific treatment. It aims to enroll 30 men.
- What's involved
- Participants will give themselves weekly injections of tirzepatide following manufacturer instructions. The study will last through the day of surgery, which is an average of 1 year.
- Compensation
- Not stated in the trial record.
- Follow-up
- Safety and adverse events will be measured through study completion, an average of 1 year.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
NCT06759701
Pre-Surgical Tirzepatide-Assisted Weight Loss in Overweight and Obese Men With Intermediate Risk Prostate Cancer: A Pilot Feasibility Study
Recruiting
EARLY_PHASE1Ages 18+InterventionalTreatmentM.D. Anderson Cancer CenterInvestigator-initiated
~30 participants
Updated 2026-02-27 on ClinicalTrials.gov
What's tested:Tirzepatide
At a glance
Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Safety and Adverse Events (AEs)
Measured over Through study completion; an average of 1 year
Conditions
Where it's being run
1 sites across 1 statesTexas1
Study leadership
- Justin Gregg, MD · PRINCIPAL_INVESTIGATOR · M.D. Anderson Cancer Center
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
Do you actually qualify for this trial?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Eligibility criteria
Inclusion
Histologically confirmed adenocarcinoma of the prostate that is localized (no metastatic lesions or concerning lymph nodes 1cm or greater) based on prostate MRI and meets NCCN intermediate risk criteria (as follows):
Clinical T2b-T2c or lower disease
Gleason Grade group 2 or 3 on biopsy
PSA ≤20 ng/mL
Desires radical prostatectomy (open or robotic) for prostate cancer management and is a surgical candidate as determined by the treating urologic oncologist
Adult men \>30 and \< 75 years old
Currently diagnosed with Diabetes Mellitus and meet one of the following criteria for overweight or obesity:
Body Mass Index (BMI) greater than or equal to 27 kg/m2
Waist circumference (\> 40 inches) -or-
Currently have a BMI greater or equal to 30 kg/m2 -or-
Currently have a BMI greater or equal to 27 kg/m2 with at least one weight-related condition, defined as one or more of the following:
Hypertension: treated or with systolic blood pressure (SBP) ≥130 mmHg or diastolic blood pressure ≥80 mmHg
Dyslipidemia: treated or with low-density lipoprotein (LDL) ≥160 mg/dL (4.1 mmol/L) or triglycerides ≥150 mg/dL (1.7 mmol/L), or high-density lipoprotein (HDL) \<40mg/dL (1.0 mmol/L)
Obstructive sleep apnea
Cardiovascular disease (for example, ischemic cardiovascular disease, New York Heart Association (NYHA) Functional Class I-III heart failure)
Exclusion
Prostate cancer that meets factors as part of NCCN high and very high-risk criteria (as follows):
pT3a or higher disease
Grade group 4 or 5 adenocarcinoma of prostate
Presence of metastatic disease on imaging
A history of intentional or unintentional weight loss of more than 5kg within 90 days of screening
Any prior androgen deprivation, chemotherapy, surgery, or radiation for PCa
Previous or planned surgical treatment for obesity or use of a medication that promotes weight loss within 90 days before screening
Have renal impairment measured as estimated glomerular filtration rate (eGFR) \<30 as determine using standard MD Anderson laboratory measures
Have a known clinically significant gastric emptying abnormality (for example, severe diabetic gastroparesis or gastric outlet obstruction) or chronically take drugs that directly affect GI motility
Have had a history of chronic or acute pancreatitis
Have a history of significant active or unstable Major Depressive Disorder (MDD) or other severe psychiatric disorder (for example, schizophrenia, bipolar disorder, or other serious mood or anxiety disorder) within the last 2 years
Note: Patients with MDD or generalized anxiety disorder whose disease state is considered stable and expected to remain stable throughout the course of the study, in the opinion of the investigator, may be considered for inclusion if they are not on excluded medications
Have any of the following cardiovascular conditions within 3 months prior to study enrollment: acute myocardial infarction (MI), cerebrovascular accident (stroke), unstable angina, or hospitalization due to congestive heart failure (CHF)
Have NYHA Functional Classification IV CHF
Have acute or chronic hepatitis, signs, and symptoms of any other liver disease other than nonalcoholic fatty liver disease, or any of the following, as determined by the central laboratory during screening: - alanine aminotransferase (ALT) level \>3.0X the upper limit of normal (ULN) for the reference range or - alkaline phosphatase (ALP) level \>1.5X the ULN for the reference range or - total bilirubin level \>1.2X the ULN for the reference range (except for cases of known Gilbert's Syndrome) Note: Participants with nonalcoholic fatty liver disease are eligible to participate in this trial if their ALT level is ≤3.0X the ULN for the reference range
Have a family or personal history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia (MEN) Syndrome type 2
Have a history of an active or untreated malignancy or are in remission from a clinically significant malignancy (other than basal- or squamous-cell skin cancer, in situ carcinomas of the cervix), other than prostate cancer, for less than 5 years
Have any other condition not listed in this section (for example, hypersensitivity or intolerance) that is a contraindication to GLP-1R agonists
Have a history of any other condition (such as known drug or alcohol abuse, diagnosed eating disorder, or other psychiatric disorder) that, in the opinion of the investigator, may preclude the participant from following and completing the protocol
Have history of use of marijuana within 3 months of enrollment and unwillingness to abstain from marijuana use during the trial. Participants should also refrain from use of cannabidiol oil for the duration of the study
Have had a transplanted organ (corneal transplants \[keratoplasty\] allowed) or awaiting an organ transplant.
What this trial measures
- Safety and Adverse Events (AEs)Through study completion; an average of 1 year
Incidence of Adverse Events, Graded According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version (v) 5.0